Recurrence Patterns and Survival Outcomes in Clinical Stage IIB/IIC Melanoma: Can We Stratify Patients for Consideration of Neoadjuvant Immunotherapy?
This single-institution retrospective cohort study of patients with clinical stage IIB/IIC melanoma found a 2-year RFS of 69%. The presence of pre-surgical lymphovascular invasion was significantly associated with recurrence in this population. These data can help guide clinicians and researchers in the design and assessment of future studies evaluating neoadjuvant therapy in clinical stage IIB/IIC melanoma and in optimizing patient selection.
Authors
- John T. Miura (ORCID: https://orcid.org/0000-0001-7028-2152)
- Mohammad Saad Farooq (ORCID: https://orcid.org/0009-0009-8493-6976)
- Pankaj Beniwal
- Giorgos C. Karakousis (ORCID: https://orcid.org/0000-0002-9321-2795)
- Neha Shafique (ORCID: https://orcid.org/0000-0001-7219-2839)
- G Vargas (ORCID: https://orcid.org/0000-0002-5963-4513)
- Valentina Mattfeld
Institutions
- Hospital of the University of Pennsylvania (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Annals of Surgical Oncology
- Published
- 2025-09-04
- DOI
- https://doi.org/10.1245/s10434-025-18263-z
- Citations
- 4
- Primary Topic
- Cutaneous Melanoma Detection and Management
- Type
- article
- Field-Weighted Citation Impact
- 4.18
Funders
- University of Pennsylvania